

**Prof. Dr. med. Christian Jackisch**  
**Publikationsliste – Liste der peer reviewed Publikationen – update 06/2012**

---

- 1. ABC1 Consensus Conference - a German Perspective: First International Consensus Conference on Advanced Breast Cancer (ABC1), Lisbon, November 5, 2011.**  
Thomssen C, Marschner N, Untch M, Decker T, Hegewisch-Becker S, **Jackisch C**, Janni W, Hans-Joachim L, von Minckwitz G, Scharl A, Schneeweiss A, Tesch H, Welt A, Harbeck N. Breast Care (Basel). 2012 Feb;7(1):52-59. Epub 2012 Jan 30.
- 4. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.**  
Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, **Jackisch C**, Huober J, Kühn T, Nekljudova V, von Minckwitz G; German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lancet Oncol. 2012 Feb;13(2):135-44. Epub 2012 Jan 17.
- 5. Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial.**  
Rayson D, Suter TM, **Jackisch C**, van der Vegt S, Bermejo B, van den Bosch J, Vivanco GL, van Gent AM, Wildiers H, Torres A, Provencher L, Temizkan M, Chirgwin J, Canon JL, Ferrandina G, Srinivasan S, Zhang L, Richel DJ. Ann Oncol. 2012 May 23. [Epub ahead of print]
- 6. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.**  
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. Lancet. 2011 Nov 12;378(9804):1707-16. Epub 2011 Oct 19.
- 7. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.**  
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R.
- 8. The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer.**  
von Minckwitz G, Loibl S, **Jackisch C**, Paepke S, Nestle-Kraemling C, Lux MP, Maass N, Schmutzler R, du Bois A, Wallwiener D, Vescia S, Budischewski K, Kaufmann M. Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2141-9. Epub 2011 Jul 27.
- 9. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.**  
Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, **Jackisch C**, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R; Herceptin Adjuvant (HERA) Trial Study Team. Lancet Oncol. 2011 Mar;12(3):236-44. Epub 2011 Feb 25.
- 10. Comparing guidelines for adjuvant endocrine therapy in postmenopausal women with breast cancer: a coming of age.**  
Verma S, **Jackisch C**. Expert Rev Anticancer Ther. 2011 Feb;11(2):277-86. Review.
- 11. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.**  
von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Mehta K, Hilfrich J, **Jackisch C**, Gerber B, du Bois A,

Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jüni P. *Breast Cancer Res Treat.* 2011 Jan;125(1):145-56. Epub 2010 Nov 3.

12. **Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer.**  
Gevensleben H, Göhring UJ, Büttner R, Heukamp LC, Kunz G, Dimpfl T, **Jackisch C**, Ortmann O, Albert US, Bender R, De Snoo F, Krijgsman O, Glas AM, Ergönenc YH, Vogel C, Dykgers A, Langwieder C, Rees M, Anzeneder T.  
*Int J Mol Med.* 2010 Dec;26(6):837-43.
13. **Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.**  
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S.  
*J Natl Cancer Inst Monogr.* 2010;2010(41):162-77. Review.
14. **Future Roles of Lapatinib in ErbB2-Positive Breast Cancer: Adjuvant and Neoadjuvant Trials.**  
Costa SD, **Jackisch C**, Thomssen C.  
*Breast Care (Basel).* 2010;5(s1):22-24. Epub 2010 Apr 26.
15. **Systemic Therapy for Women with ErbB2-Positive Breast Cancer: New Options, New Challenges.**  
**Jackisch C**, Untch M.  
*Breast Care (Basel).* 2010;5(s1):1-2. Epub 2010 Apr 26.
16. **Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.**  
du Bois A, Herrstedt J, Hardy-Bessard AC, Müller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, **Jackisch C**, Sehouli J.  
*J Clin Oncol.* 2010 Sep 20;28(27):4162-9. Epub 2010 Aug 23.
17. **Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer.**  
Müller V, Thomssen C, Schmidt M, Glados M, **Jackisch C**, Heilmann V, Hinke A, Lehnert A, Borowicz H, Möbus V.  
*BMC Cancer.* 2010 Aug 16;10:430.
18. **Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies.**  
Lebeau A, Turzynski A, Braun S, Behrhof W, Fleige B, Schmitt WD, Grob TJ, Burkhardt L, Hölzel D, **Jackisch C**, Thomssen C, Müller V, Untch M.  
*J Clin Oncol.* 2010 Jul 10;28(20):3264-70. Epub 2010 May 24.
19. **Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.**  
Pujade-Lauraine E, Wagner U, Avall-Lundqvist E, GebSKI V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, **Jackisch C**, Joly F, Brown C, Le Fur N, du Bois A.  
*J Clin Oncol.* 2010 Jul 10;28(20):3323-9. Epub 2010 May 24.
20. **Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.**  
Moebus V, **Jackisch C**, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M.  
*J Clin Oncol.* 2010 Jun 10;28(17):2874-80. Epub 2010 May 10.
21. **Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.**  
von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J,

Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, **Jackisch C**, Kaufmann M, Mehta K, Untch M.  
J Clin Oncol. 2010 Apr 20;28(12):2015-23. Epub 2010 Mar 22.

- 22. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.**  
Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, **Jackisch C**, Kaufmann M, Mehta K, von Minckwitz G.  
J Clin Oncol. 2010 Apr 20;28(12):2024-31. Epub 2010 Mar 22.
- 23. Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study.**  
Schwenkglenks M, Pettengell R, **Jackisch C**, Paridaens R, Constenla M, Bosly A, Szucs TD, Leonard R.  
Support Care Cancer. 2011 Apr;19(4):483-90. Epub 2010 Mar 20.
- 24. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.**  
Untch M, Muscholl M, Tjulandin S, Jonat W, Meerpohl HG, Lichinitser M, Manikhas AG, Coumbos A, Kreienberg R, du Bois A, Harbeck N, **Jackisch C**, Müller V, Pauschinger M, Thomssen C, Lehle M, Catalani O, Lück HJ.  
J Clin Oncol. 2010 Mar 20;28(9):1473-80. Epub 2010 Feb 22.
- 25. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data.**  
Costa SD, Loibl S, Kaufmann M, Zahm DM, Hilfrich J, Huober J, Eidtmann H, du Bois A, Blohmer JU, Ataseven B, Weiss E, Tesch H, Gerber B, Baumann KH, Thomssen C, Breitbach GP, Ibishi S, **Jackisch C**, Mehta K, von Minckwitz G.
- 26. Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment.**  
Reinartz S, Pfisterer J, du Bois A, **Jackisch C**, Baumann KH, Wagner U.  
Hum Immunol. 2010 Jan;71(1):36-44. Epub .
- 27. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.**  
Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, **Jackisch C**, Dietel M, Richter K, Kaufmann M, von Minckwitz G.  
Breast Cancer Res. 2009;11(5):R69.
- 28. Restrictive dermopathy: a rare laminopathy.**  
Thill M, Nguyen TD, Wehnert M, Fischer D, Hausser I, Braun S, **Jackisch C**.  
Arch Gynecol Obstet. 2008 Sep;278(3):201-8. Epub 2008 May 10.
- 29. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.**  
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, **Jackisch C**, Loibl S, Mehta K, Kaufmann M; German Breast Group.  
J Natl Cancer Inst. 2008 Apr 16;100(8):542-51. Epub 2008 Apr 8.

- 30. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.**  
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, **Jackisch C**, Loibl S, Mehta K, Kaufmann M; German Breast Group.  
J Natl Cancer Inst. 2008 Apr 16;100(8):552-62. Epub 2008 Apr 8.
- 31. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently in patients with operable carcinoma of the breast.**  
von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, **Jackisch C**, Costa SD, Caputo A, Kaufmann M; German Breast Group.  
Breast Cancer Res. 2008;10(2):R30. Epub 2008 Apr 1.
- 32. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study.**  
Pettengell R, Schwenkglenks M, Leonard R, Bosly A, Paridaens R, Constenla M, Szucs TD, **Jackisch C**; Impact of Neutropenia in Chemotherapy-European Study Group (INC-EU).  
Support Care Cancer. 2008 Nov;16(11):1299-309. Epub 2008 Mar 20.
- 33. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.**  
Untch M, Gelber RD, **Jackisch C**, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Constantin C, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkus-Konefka E, Price C, Haslbauer F, Suarez Sahui T, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A; HERA Study Team.  
Ann Oncol. 2008 Jun;19(6):1090-6. Epub 2008 Feb 21.
- 34. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.**  
Gluz O, Nitz UA, Harbeck N, Ting E, Kates R, Herr A, Lindemann W, **Jackisch C**, Berdel WE, Kirchner H, Metzner B, Werner F, Schütt G, Frick M, Poremba C, Diallo-Danebrock R, Mohrmann S; West German Study Group.  
Ann Oncol. 2008 May;19(5):861-70. Epub 2008 Jan 3.
- 35. Adherence to Treatment Guidelines in Breast Cancer Care - a Retrospective Analysis of the 'Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie'**  
**Jackisch C**, Untch M, Chatsiproios D, Lamparter C, Overkamp F, Lichtenegger W, Rösberg W, Thomssen C, von Minckwitz G, Albert US.  
Breast Care (Basel). 2008;3(2):87-92. Epub 2008 Apr 25.
- 36. Development of Targeted Therapies in ErbB2-Positive Breast Cancer.**  
**Jackisch C**, Rüschoff J, Ullrich A.  
Breast Care (Basel). 2008;3(s1):3-6. Epub 2008 Apr 24.
- 37. Treatment Options in ErbB2 (HER2)-Overexpressing Breast Cancer.**  
**Jackisch C**.  
Breast Care (Basel). 2008;3(s1):1.
- 38. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPAR DUO trial.**  
Loibl S, von Minckwitz G, Raab G, Blohmer JU, Dan Costa S, Gerber B, Eidtmann H, Petrich S, Hilfrich J, **Jackisch C**, du Bois A, Kaufmann M.  
Ann Surg Oncol. 2006 Nov;13(11):1434-42. Epub 2006 Sep 17.
- 39. HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy.**  
**Jackisch C**. Oncologist. 2006;11 Suppl 1:34-41. Review.
- 40. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.**

Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E; AGO-OVAR; NCIC CTG; EORTC GCG. *J Clin Oncol*. 2006 Oct 10;24(29):4699-707. Epub 2006 Sep 11.

- 41. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.**  
Kröger N, Frick M, Gluz O, Mohrmann S, Metzner B, **Jackisch C**, Ko Y, Lindemann HW, Meier CR, Lohrmann HP, Ruffert U, Hänel M, Bodenstern H, Neubauer A, Ehninger G, Wolf HH, Kolbe K, Burock K, Zander AR, Nitz U.  
*J Clin Oncol*. 2006 Aug 20;24(24):3919-26.
- 42. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.**  
Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, **Jackisch C**, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR; GINECO. *J Natl Cancer Inst*. 2006 Aug 2;98(15):1036-45.
- 43. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment.**  
Schwenkglens M, **Jackisch C**, Constenla M, Kerger JN, Paridaens R, Auerbach L, Bosly A, Pettengell R, Szucs TD, Leonard R.  
*Support Care Cancer*. 2006 Sep;14(9):901-9. Epub 2006 Apr 19.
- 44. [Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer].**  
Hooper J, **Jackisch C**, Untch M, Möbus V, Wallwiener D, Kaufmann M, Minckwitz G.  
*Zentralbl Gynakol*. 2006 Feb;128(1):30-7.
- 45. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu.**  
Diallo R, Rody A, **Jackisch C**, Ting E, Schaefer KL, Kissler S, Karn T, Geddert H, Engels K, Kaufmann M, Gabbert HE, Shroyer KR, Poremba C.  
*Hum Pathol*. 2006 Feb;37(2):205-11.
- 46. The role of surgery in recurrent ovarian cancer.**  
Pfisterer J, Harter P, Canzler U, Richter B, **Jackisch C**, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Hooper J, Fink D, Bois A; AGO Ovarian Committee; AGO Ovarian Cancer Study Group (AGO-OVAR)  
*Int J Gynecol Cancer*. 2005 Nov-Dec;15 Suppl 3:195-8.
- 47. Bone metastases in vulvar cancer: a rare metastatic pattern.**  
Fischer F, Kuhl M, Feek U, Rominger M, Schipper ML, Hadji P, Wagner U, **Jackisch C**.  
*Int J Gynecol Cancer*. 2005 Nov-Dec;15(6):1173-6.
- 48. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.**  
Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, **Jackisch C**, Werner C, Ziske C, Kirchner H, Metzner B, Souchon R, Ruffert U, Schütt G, Pollmanns A, Schmoll HJ, Middecke C, Baltzer J, Schrader I, Wiebringhaus H, Ko Y, Rösel S, Schwenzer T, Wernet P, Hinke A, Bender HG, Frick M; West German Study Group.  
*Lancet*. 2005 Dec 3;366(9501):1935-44. Erratum in: *Lancet*. 2006 Mar 4;367(9512):730.
- 49. Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR).**  
**du Bois A, Burges A, Meier W, Pfisterer J, Schmalfeldt B, Richter B, Jackisch C, Staehle A, Kimmig R, Elser G; Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom**

Ann Oncol. 2006 Jan;17:93-6. Epub 2005 Nov 9.

- 50. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.**  
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, **Jackisch C**, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greaux V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team.  
N Engl J Med. 2005 Oct 20;353(16):1659-72.
- 51. Radiation-induced capsule tissue reactions around textured breast implants in a rat model.**  
Eltze E, Schäfer U, Bettendorf O, Rody A, Herchenröder F, Chiwritsch T, **Jackisch C**, Pfeleiderer B.  
Breast. 2006 Jun;15(3):331-8. Epub 2005 Oct 17.
- 52. Mammographic breast density and breast cancer risk during HRT.**  
Bock K, Hadji P, Duda VF, **Jackisch C**, Wagner U.  
Zentralbl Gynakol. 2005 Aug;127(4):217-21.
- 53. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDO study of the German Breast Group.**  
von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe D, **Jackisch C**, du Bois A, Kaufmann M.  
J Clin Oncol. 2005 Apr 20;23(12):2676-85.
- 54. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.**  
Stemmler J, Mair W, Stauch M, Papke J, Deutsch G, Abenhardt W, Dorn B, Kentenich C, Malekmohammadi M, **Jackisch C**, Leinung S, Brudler O, Vehling-Kaiser U, Stamp J, Heinemann V.  
Oncology. 2005;68(1):71-8. Epub 2005 Mar 12.
- 55. Androgen receptor expression in ductal carcinoma in situ of the breast: not a helpful marker for classification such as estrogen receptor alpha and progesterone receptor.**  
Rody A, Diallo R, Poremba C, Wuelfing P, Kissler S, Solbach C, Kaufmann M, **Jackisch C**.  
Appl Immunohistochem Mol Morphol. 2005 Mar;13(1):25-9.
- 56. Anthracycline and trastuzumab in breast cancer treatment.**  
Untch M, Himsl I, Kahlert S, Lueck HJ, Eidtmann H, Du Bois A, Meerpohl HG, Thomssen C, Harbeck N, **Jackisch C**, Kreienberg R, Emons G, Wallwiener D, Wiese W, Schaller G, Kuhn W, Muscholl M, Pauschinger M, Langer B.  
Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):59-64.
- 57. A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).**  
du Bois A, Belau A, Wagner U, Pfisterer J, Schmalfeldt B, Richter B, Staehle A, **Jackisch C**, Lueck HJ, Schroeder W, Burges A, Olbricht S, Elser G; for the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).  
Gynecol Oncol. 2005 Feb;96(2):444-51.
- 58. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.**  
von Minckwitz G, Blohmer JU, Raab G, Löhr A, Gerber B, Heinrich G, Eidtmann H, Kaufmann M, Hilfrich J, **Jackisch C**, Zuna I, Costa SD; German Breast Group.  
Ann Oncol. 2005 Jan;16(1):56-63.

59. **Future options with trastuzumab for primary systemic and adjuvant therapy.**  
Baselga J, Gianni L, Geyer C, Perez EA, Riva A, **Jackisch C**.  
Semin Oncol. 2004 Oct;31(5 Suppl 10):51-7.
60. **Management of breast cancer treatment -- a multidisciplinary approach].**  
**Jackisch C**, Rezai M, Eiermann W, Jonat W, Kaufmann M.  
Zentralbl Gynakol. 2004 Oct;126(5):303-5.
61. **Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.**  
Rody A, Diallo R, Poremba C, Speich R, Wuelfing P, Kissler S, Solbach C, Kiesel L, **Jackisch C**.  
Oncol Rep. 2004 Oct;12(4):695-9.
62. **Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.**  
Untch M, Eidtmann H, du Bois A, Meerpohl HG, Thomssen Ch, Ebert A, Harbeck N, **Jackisch C**, Heilman V, Emons G, Wallwiener D, Wiese W, Blohmer JU, Höffken K, Kuhn W, Reichardt P, Muscholl M, Pauschinger M, Langer B, Lück HJ.  
Eur J Cancer. 2004 May;40(7):988-97.
63. **Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry.**  
Diallo R, Schaefer KL, Bankfalvi A, Decker T, Ruhnke M, Wülfing P, **Jackisch C**, Luttes J, Sorensen PH, Singh M, Poremba C.  
Hum Pathol. 2003 Dec;34(12):1299-305.
64. **A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.**  
du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, **Jackisch C**, Emons G, Wagner U, Kuhn W, Pfisterer J; Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.  
J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9.
65. **Lung cancer during pregnancy involving the products of conception and a review of the literature.**  
**Jackisch C**, Louwen F, Schwenkhagen A, Karbowski B, Schmid KW, Schneider HP, Holzgreve W.  
Arch Gynecol Obstet. 2003 Jun;268(2):69-77. Epub 2002 Nov 21.
66. **Influence of local complications on capsule formation around model implants in a rat model.**  
Eltze E, Bettendorf O, Rody A, **Jackisch C**, Herchenröder F, Böcker W, Pfeleiderer B.  
J Biomed Mater Res A. 2003 Jan 1;64(1):12-9.
67. **Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.**  
**Jackisch C**, von Minckwitz G, Eidtmann H, Costa SD, Raab G, Blohmer JU, Schütte M, Gerber B, Merkle E, Gademann G, Lampe D, Hilfrich J, Tulusan AH, Caputo A, Kaufmann M.  
Clin Breast Cancer. 2002 Oct;3(4):276-80.
68. Endobronchial mucosal metastases in breast cancer: a rare metastatic pattern.  
**Jackisch C**, Gast B, Bánkfalvi A, Diallo R, Lerchenmüller C, Kiesel L.  
Lancet Oncol. 2002 Nov;3(11):702-3.
69. **Evidence-based recommendations on primary treatment of carcinomas of the breast**  
Von Minckwitz G, Brunnert K, Costa SD, Friedrichs K, Jackisch Ch, Gerber B, Harbeck N, Junkermann H, Möbus V, Nitz U, Schaller G, Scharl A, Thomssen Ch, Untch M; Consensus

of the AGO Organ Commission "Mamma".  
Zentralbl Gynakol. 2002 May;124(5):293-303.

70. **Clinical management of breast cancer in males: a report of four cases.**  
Heinig J, **Jackisch C**, Rody A, Koch O, Buechter D, Schneider HP.  
Eur J Obstet Gynecol Reprod Biol. 2002 Apr 10;102(1):67-73.
71. **Comparative examination of complaints of patients with breast-cancer with and without silicone implants.**  
Berner I, Gaubitz M, **Jackisch C**, Pfeleiderer B.  
Eur J Obstet Gynecol Reprod Biol. 2002 Apr 10;102(1):61-6.
72. **Silicone breast implants: correlation between implant ruptures, magnetic resonance spectroscopically estimated silicone presence in the liver, antibody status and clinical symptoms.**  
Gaubitz M, **Jackisch C**, Domschke W, Heindel W, Pfeleiderer B.  
Rheumatology (Oxford). 2002 Feb;41(2):129-35;
73. **Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.**  
du BA, Meier W, Lück HJ, Emon G, Moebus V, Schroeder W, Costa S, Bauknecht T, Olbricht S, **Jackisch C**, Richter B, Wagner U.  
Ann Oncol. 2002 Feb;13(2):251-7.
74. **The conservative management of adnexal torsion--a case-report and review of the literature.**  
Rody A, **Jackisch C**, Klockenbusch W, Heinig J, Coenen-Worch V, Schneider HP.  
Eur J Obstet Gynecol Reprod Biol. 2002 Feb 10;101(1):83-6
75. **Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group.**  
von Minckwitz G, Raab G, Schütte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe D, **Jackisch C**, du Bois A, Tulusan AH, Gademann G, Sinn HP, Caputo A, Graf E, Kaufmann M.  
Zentralbl Gynakol. 2001 Sep;123(9):497-504.
76. **Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study.**  
von Minckwitz G, Costa SD, Raab G, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, **Jackisch C**, Gademann G, Tulusan AH, Eiermann W, Graf E, Kaufmann M; German Preoperative Adriamycin-Docetaxel and German Adjuvant Breast Cancer Study Groups.  
J Clin Oncol. 2001 Aug 1;19(15):3506-15.
77. **Malignant melanoma and pregnancy**  
Karbowski B, **Jackisch C**.  
Z Geburtshilfe Neonatol. 2000 Jul-Aug;204(4):158-61.
78. **Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells.**  
**Jackisch C**, Hahm HA, Tombal B, McCloskey D, Butash K, Davidson NE, Denmeade SR.  
Clin Cancer Res. 2000 Jul;6(7):2844-50.
79. **Acceptance of hospital social work by gynecological oncology patients**  
Bönninghaus-John S, **Jackisch C**, Schneider HP.



Zentralbl Gynakol. 1999;121(11):513-21. German.

- 80. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel.**  
von Minckwitz G, Costa SD, Eiermann W, Blohmer JU, Tulusan AH, **Jackisch C**, Kaufmann M.  
J Clin Oncol. 1999 Jul;17(7):1999-2005.
- 81. Relationship of estrogen and progesterone receptors to the menstrual cycle and menopausal status at the time of breast surgery.**  
Karbowski B, **Jackisch C**, Deppe B, Schneider HP.  
Zentralbl Gynakol. 1999;121(8):367-74.
- 82. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.**  
Costa SD, von Minckwitz G, Raab G, Blohmer JU, Dresel V, Eidtmann H, Hilfrich J, **Jackisch C**, Merkle E, Gademann G, Kaufmann M.  
Semin Oncol. 1999 Jun;26(3 Suppl 9):24-31.
- 83. Peutz-Jeghers syndrome: four novel inactivating germline mutations in the STK11 gene. Mutations in brief no. 227. Online.**  
Kruse R, Uhlhaas S, Lamberti C, Keller KM, **Jackisch C**, Steinhard J, Knöpfle G, Loff S, Back W, Stolte M, Jungck M, Propping P, Friedl W, Jenne DE.  
Hum Mutat. 1999;13(3):257-8.
- 84. Potential benefits of estrogens and progestogens on breast cancer.**  
Schneider HP, **Jackisch C**.  
Int J Fertil Womens Med. 1998 Nov-Dec;43(6):278-85.
- 85. Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model.**  
Roetger A, Merschjann A, Dittmar T, **Jackisch C**, Barnekow A, Brandt B.  
Am J Pathol. 1998 Dec;153(6):1797-806.
- 86. Current developments in use of docetaxel (taxotere) in gynecologic oncology**  
**Jackisch C.**  
Med Klin (Munich). 1998 Sep 15;93 Suppl 3:4-15.
- 87. Peripheral blood stem cell transplantation as an interdisciplinary challenge--theory and practice.**  
Cassens U, **Jackisch C**, Garritsen HS, Schneider HP, Sibrowski W.  
Zentralbl Gynakol. 1998;120(8):367-72.
- 88. Plasma and membrane Ca<sup>2+</sup> and Mg<sup>2+</sup> concentrations in normal pregnancy and in preeclampsia.**  
Kisters K, Körner J, Louwen F, Witteler R, **Jackisch C**, Zidek W, Ott S, Westermann G, Barenbrock M, Rahn KH.  
Gynecol Obstet Invest. 1998;46(3):158-63.
- 89. Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients.**  
Brandt B, Roetger A, Heidl S, **Jackisch C**, Lelle RJ, Assmann G, Zänker KS.  
Int J Cancer. 1998 Jun 10;76(6):824-8.
- 90. Translational research studies of erbB oncogenes: selection strategies for breast cancer treatment.**  
Brandt BH, Beckmann A, Gebhardt F, Rötger A, **Jackisch C**, Assmann G, Zänker KS.  
Cancer Lett. 1997 Oct 14;118(2):143-51.
- 91. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.**  
du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Warm M, Bauknecht T, Schröder

- W, Olbricht S, Nitz U, **Jackisch C**.  
Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-44-S15-52.
92. **Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.**  
du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Bauknecht T, Warm M, Schroeder W, Olbricht S, Nitz U, **Jackisch C**.  
Semin Oncol. 1997 Aug;24(4 Suppl 11):S11-28-S11-33.
93. **Psychosocial acceptance of surgical interventions of the breast in oncological gynecology**  
**Jackisch C**, Leinweber M, Küchenmeister U, Muthny FA, Schneider HP.  
Zentralbl Gynakol. 1997;119(5):218-24.
94. **Significance of stem cell-supported high-dose chemotherapy in the treatment of gynecological malignancies: indications and current clinical trials in the Federal Republic of Germany**  
Nitz U, Frick M, Adomeit A, **Jackisch C**, Schwenkhagen A, Möbus V, Bender HG.  
Zentralbl Gynakol. 1997;119(5):195-203.
95. **Malignant melanoma of the vulva. Report of 89 patients.**  
Räber G, Mempel V, **Jackisch C**, Hundeiker M, Heinecke A, Kürzl R, Glaubitz M, Rompel R, Schneider HP.  
Cancer. 1996 Dec 1;78(11):2353-8.
96. **Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells.**  
Pizer ES, **Jackisch C**, Wood FD, Pasternack GR, Davidson NE, Kuhajda FP.  
Cancer Res. 1996 Jun 15;56(12):2745-7.
97. **Programmed cell death in human breast cancer cells.**  
McCloskey DE, Armstrong DK, **Jackisch C**, Davidson NE.  
Recent Prog Horm Res. 1996;51:493-508.
98. **Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: double-differential polymerase chain reaction (ddPCR) for clinical diagnosis.**  
Brandt B, Vogt U, Schlotter CM, **Jackisch C**, Werkmeister R, Thomas M, von Eiff M, Bosse U, Assmann G, Zänker KS.  
Gene. 1995 Jun 14;159(1):35-42.
99. **Interventional therapy of inferior vena cava thrombosis in pregnancy--use of a new kind of temporary vena cava filter**  
**Jackisch C**, Schwenkhagen A, Budde T, Louwen F, Meschede D, Schober O, Holzgreve W, Schneider HP.  
Zentralbl Gynakol. 1995;117(4):181-9.
100. **Endocrine management of breast cancer.**  
Schneider PG, **Jackisch C**, Brandt B.  
Int J Fertil Menopausal Stud. 1994;39 Suppl 2:115-27.
101. **Dose intensified carboplatin monotherapy in advanced ovarian cancer**  
Nitz U, **Jackisch C**, Weise W, Schiller E, Illiger HJ.  
Zentralbl Gynakol. 1994;116(10):549-54.
102. **Echinococcosis in pregnancy. A rare differential diagnosis in cystic intra-abdominal tumors in pregnancy.**  
**Jackisch C**, Schwenkhagen A, Louwen F, Räber G, Oehme A, Schneider HP.  
Zentralbl Gynakol. 1993;115(6):263-72.

103. **Primary malignant melanoma of the uterine cervix--case report and review of the literature.**  
Räber G, Mempel V, **Jackisch C**, Patt V, Schneider HP.  
Zentralbl Gynakol. 1993;115(11):503-7.
104. **Clinical aspects of primary malignant melanoma of the vagina.**  
Räber G, Mempel V, **Jackisch C**, Schneider HP.  
Zentralbl Gynakol. 1993;115(9):416-22.
105. **Cervix cancer in HPV16-associated Bowenoid papulosis**  
Böhmer B, Hamm H, **Jackisch C**, Bonsmann G.  
Geburtshilfe Frauenheilkd. 1992 Jul;52(7):438-41.
106. **Possibilities of surgical management of local recurrence and radiogenic chest wall damage using the latissimus dorsi transposed flap in advanced breast cancer**  
Behling H, **Jackisch C**, Hagemann HA.  
Zentralbl Gynakol. 1991;113(24):1364-70.
107. **Breast cancer imaging with radioiodinated oestradiol.**  
Schober O, Scheidhauer K, **Jackisch C**, Schicha H, Smolarz K, Bolte A, Reiners C, Höffken K, Biersack HJ, Briele B, et al.  
Lancet. 1990 Jun 23;335(8704):1522. No abstract available.